Equities analysts expect that Merck & Co., Inc. (NYSE:MRK) will report sales of $10.89 billion for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Merck & Co., Inc.’s earnings, with the lowest sales estimate coming in at $10.82 billion and the highest estimate coming in at $11.01 billion. Merck & Co., Inc. reported sales of $10.33 billion during the same quarter last year, which would suggest a positive year over year growth rate of 5.4%. The firm is scheduled to announce its next earnings results on Friday, October 26th.
On average, analysts expect that Merck & Co., Inc. will report full-year sales of $42.36 billion for the current fiscal year, with estimates ranging from $42.24 billion to $42.59 billion. For the next fiscal year, analysts anticipate that the business will post sales of $43.14 billion per share, with estimates ranging from $42.17 billion to $43.95 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Merck & Co., Inc..
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, July 27th. The company reported $1.06 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.03. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The company had revenue of $10.47 billion for the quarter, compared to analysts’ expectations of $10.28 billion. During the same quarter last year, the business earned $1.01 earnings per share. Merck & Co., Inc.’s revenue was up 5.4% on a year-over-year basis.
A number of brokerages have weighed in on MRK. Bank of America upped their target price on Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. BMO Capital Markets restated a “buy” rating and issued a $70.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, July 22nd. Jefferies Financial Group restated a “hold” rating and issued a $59.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, July 15th. Zacks Investment Research lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, June 18th. Finally, TheStreet upgraded Merck & Co., Inc. from a “c+” rating to a “b-” rating in a research note on Friday, June 8th. Six investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $66.24.
In other Merck & Co., Inc. news, EVP Julie L. Gerberding sold 9,972 shares of the stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $59.66, for a total value of $594,929.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Kenneth C. Frazier sold 228,091 shares of the stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total value of $14,825,915.00. Following the completion of the sale, the chairman now owns 938,788 shares of the company’s stock, valued at approximately $61,021,220. The disclosure for this sale can be found here. Insiders have sold a total of 406,365 shares of company stock valued at $25,829,990 over the last 90 days. 0.32% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Clearwater Capital Advisors LLC purchased a new position in shares of Merck & Co., Inc. in the first quarter valued at about $103,000. SRS Capital Advisors Inc. increased its position in shares of Merck & Co., Inc. by 208.4% in the 1st quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock valued at $108,000 after acquiring an additional 1,340 shares during the period. Santori & Peters Inc. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $110,000. Taylor Wealth Management Partners acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at $110,000. Finally, Creative Financial Designs Inc. ADV increased its position in shares of Merck & Co., Inc. by 155.2% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock valued at $111,000 after acquiring an additional 1,114 shares during the period. Institutional investors and hedge funds own 73.08% of the company’s stock.
NYSE MRK traded up $0.07 during trading on Tuesday, reaching $66.07. The company’s stock had a trading volume of 7,439,672 shares, compared to its average volume of 8,021,469. The firm has a market capitalization of $177.95 billion, a P/E ratio of 16.60, a P/E/G ratio of 2.27 and a beta of 0.80. The company has a quick ratio of 1.10, a current ratio of 1.33 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a one year low of $52.83 and a one year high of $66.99.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 5th. Investors of record on Monday, September 17th will be issued a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 2.91%. The ex-dividend date is Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio is presently 48.24%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Further Reading: Trading Strategy Methods and Types
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.